Anuj Kailash Aggarwal, MD
Pain Management · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Aggarwal’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A131908 · Current
Licensed to practise in California · since 2014 · expires 2027-12-31 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$25,129
Medicare paid this office $25,129 for 162 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 40 | $4,735 | $105 |
| Long return visit (40+ min) | 22 | $4,538 | $146 |
| New patient visit (60+ min) | 19 | $2,874 | $151 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 22 | $1,423 | $43 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 27 | $564 | $14 |
Who their Medicare patients are
162 Original Medicare patients in 2024. Average age 72 · Under 65 18% · 85 and older 15% · Women 65% · Also on Medicaid 27% · Health risk score 1.47. Above the middle of the specialty; the typical pain management clinician is at 1.38.
Conditions among them: High blood pressure 72% · Depression 35% · Diabetes 30% · Chronic kidney disease 24% · Coronary heart disease 23% · Heart failure 23% · Atrial fibrillation 17% · Cancer 14% · COPD 14%.
The office billed $366,048, Medicare allowed $33,238 and paid $25,129; for 300 services of 47 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 162 | 300 | 72 | 1.47 | $366,048 | $25,129 |
| 2023 | 159 | 279 | 70 | 1.70 | $434,224 | $21,678 |
| 2022 | 248 | 384 | 70 | 1.72 | $352,771 | $27,439 |
| 2021 | 182 | 334 | 70 | 1.57 | $322,284 | $26,293 |
| 2020 | 348 | 651 | 68 | 1.80 | $662,547 | $47,004 |
| 2019 | 309 | 573 | 69 | 1.50 | $467,190 | $47,486 |
| 2018 | 108 | 203 | 71 | 1.45 | $190,385 | $16,929 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Return visit (30+ min) | 43 | $3,794 | $79 |
| Long return visit (40+ min) | 22 | $3,223 | $115 |
| New patient visit (60+ min) | 16 | $2,554 | $160 |
| Injection of trigger points, 3 or more muscles | 12 | $618 | $39 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 21 | $109 | $5 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 12 | $56 | $5 |
2022: 7 services
| Return visit (30+ min) | 58 | $5,404 | $74 |
| New patient visit (60+ min) | 26 | $3,914 | $151 |
| Long return visit (40+ min) | 25 | $3,144 | $126 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 49 | $2,173 | $34 |
| Injection of trigger points, 3 or more muscles | 18 | $855 | $39 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 19 | $91 | $5 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 15 | $70 | $5 |
2021: 6 services
| Long return visit (40+ min) | 27 | $3,771 | $130 |
| Return visit (30+ min) | 33 | $3,583 | $78 |
| New patient visit (60+ min) | 19 | $3,194 | $168 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 19 | $254 | $12 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 19 | $229 | $11 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 11 | $124 | $11 |
2020: 12 services
| New patient visit (60+ min) | 38 | $5,453 | $143 |
| Return visit (30+ min) | 62 | $4,762 | $63 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 66 | $2,907 | $36 |
| Long return visit (40+ min) | 18 | $1,745 | $97 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 11 | $1,348 | $123 |
| Injection of substance into lower spine canal using imaging guidance | 11 | $1,041 | $95 |
| Ultrasonic guidance for needle placement | 28 | $761 | $25 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 11 | $611 | $56 |
| Injection of trigger points, 3 or more muscles | 16 | $556 | $33 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 31 | $466 | $15 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 33 | $387 | $11 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 16 | $237 | $13 |
2019: 8 services
| New patient visit (60+ min) | 65 | $8,576 | $132 |
| Return visit (30+ min) | 64 | $5,764 | $65 |
| Long return visit (40+ min) | 34 | $3,339 | $95 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 14 | $1,525 | $85 |
| Injection of trigger points, 3 or more muscles | 31 | $1,426 | $34 |
| Ultrasonic guidance for needle placement | 42 | $1,200 | $26 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 15 | $633 | $40 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 31 | $330 | $10 |
2018: 5 services
| New patient visit (60+ min) | 23 | $3,412 | $148 |
| Return visit (30+ min) | 15 | $1,083 | $64 |
| Injection of trigger points, 3 or more muscles | 13 | $527 | $35 |
| Ultrasonic guidance for needle placement | 12 | $405 | $29 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 21 | $274 | $11 |
Medicaid work
$769 in 2020
Medicaid paid $769 for 30 billed services this clinician did in 2020, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 13 | $490 |
| SBSQ HOSPITAL IP/OBS CARE SF/LOW MDM 25 MINUTES | 17 | $279 |
| 2020 | 30 | 2 | 13 | $769 |
Drugs they prescribed that Part D paid
$40,224
Pharmacies billed $40,224 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 33% of their Part D prescriptions (76 of 233) in 2024. At or below the middle of the specialty; the typical pain management clinician is at 44%. Long-acting opioids: 21% of their opioid prescriptions.
210 generic and 23 brand-name prescriptions · $40,224 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tizanidine | 12 | $2,684 | $224 |
| Oxycodone | 48 | $1,589 | $33 |
| Pregabalin | 11 | $335 | $30 |
| Gabapentin | 21 | $253 | $12 |
| Ketorolac Tromethamine | 18 | $82 | $5 |
See all 6 drugs
| Tizanidine | 12 | $2,684 | $224 |
| Oxycodone | 48 | $1,589 | $33 |
| Pregabalin | 11 | $335 | $30 |
| Gabapentin | 21 | $253 | $12 |
| Ketorolac Tromethamine | 18 | $82 | $5 |
| Dexamethasone | 12 | $47 | $4 |
Year by year
| 2024 | 233 | 43 | 33% (76) | 10% | $40,224 |
| 2023 | 247 | 41 | 36% (88) | 11% | $32,030 |
| 2022 | 256 | 46 | 34% (86) | 11% | $26,413 |
| 2021 | 195 | 44 | 37% (72) | 16% | $21,477 |
| 2020 | 242 | 67 | 20% (48) | 6% | $12,849 |
| 2019 | 237 | 75 | 19% (44) | 5% | $17,591 |
| 2018 | 37 | 15 | None | None | $1,705 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Tizanidine | 14 | $2,414 | $172 |
| Lidocaine | 11 | $2,377 | $216 |
| Pregabalin | 15 | $1,746 | $116 |
| Oxycodone | 47 | $1,349 | $29 |
| Duloxetine | 24 | $465 | $19 |
| Gabapentin | 22 | $437 | $20 |
2022: 9 drugs
| Aimovig | Migraine | 12 | $8,810 | $734 |
| Oxycodone | None | 37 | $2,101 | $57 |
| Duloxetine | None | 29 | $1,531 | $53 |
| Pregabalin | None | 14 | $1,189 | $85 |
| Oxycodone-Acetaminophen | None | 17 | $669 | $39 |
| Gabapentin | None | 15 | $669 | $45 |
| Baclofen | None | 27 | $628 | $23 |
| Morphine Sulfate Er | None | 12 | $282 | $23 |
| Zonisamide | None | 11 | $186 | $17 |
2021: 6 drugs
| Buprenorphine | 15 | $5,234 | $349 |
| Oxycodone | 33 | $1,504 | $46 |
| Gabapentin | 11 | $804 | $73 |
| Pregabalin | 13 | $772 | $59 |
| Duloxetine | 25 | $734 | $29 |
| Oxycodone-Acetaminophen | 11 | $178 | $16 |
2020: 6 drugs
| Gabapentin | 34 | $892 | $26 |
| Pregabalin | 15 | $735 | $49 |
| Oxycodone | 30 | $685 | $23 |
| Duloxetine | 39 | $589 | $15 |
| Tizanidine | 16 | $460 | $29 |
| Baclofen | 23 | $292 | $13 |
2019: 5 drugs
| Duloxetine | 60 | $1,977 | $33 |
| Gabapentin | 36 | $899 | $25 |
| Oxycodone | 20 | $517 | $26 |
| Baclofen | 30 | $483 | $16 |
| Tizanidine | 16 | $213 | $13 |
2018: 1 drug
| Gabapentin | 14 | $209 | $15 |
Money from drug and device companies
$427 in 2025
| 2025 | 2 | 3 | $375 | $427 |
| 2024 | 1 | 1 | $500 | $500 |
| 2022 | 1 | 1 | None | $81 |
| 2019 | 2 | 2 | None | $482 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Merck Sharp & Dohme | None | $375 | 1 payment
|
| Stryker | Optablate | $52 | 2 payments
|
See all 3 published payments
| Stryker | Meals · 2025-12-06 | Optablate | $23 |
| Stryker | Meals · 2025-12-06 | Optablate | $29 |
| Merck Sharp & Dohme | Consulting · 2025-12-03 | None | $375 |
See earlier years (2024, 2022, 2019)
2024: $500
| Merck Sharp & Dohme | None | $500 | 1 payment
|
2022: $81
| Impel Pharmaceuticals | Trudhesa | $81 | 1 payment
|
2019: $482
| Nevro | Senza Spinal Cord Stimulation System | $248 | 1 payment
|
| Bioness | Stimrouter for Pain | $234 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1659703288
- Licence
- CA A131908California A131908: Current · expires 2027-12-31
- Trained
- University of California, San Francisco School of Medicine, 2014
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207LP2900X (207LP2900X); Federal specialty code 207L00000X (207L00000X)
- Mailing address
- 450 Broadway St, 1st Fl, Pav A, Ste A18, Redwood City, CA, 94063
- NPI first listed
- 2013-08-06
- NPI last updated
- 2024-04-08
- NPI record certified
- 2024-04-08
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 450 Broadway St, 1st Fl, Pav A, Redwood City, CA, 94063 · 300 Pasteur Dr # H3580, Stanford, CA, 94305